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ABSTRACT 43 
Background: Fever is among the most common symptoms of people living in 44 
Africa, and clinicians are challenged by the similar clinical features of a wide 45 
spectrum of potential aetiologies. 46 
Aim: To summarise recent studies of fever aetiology in sub-Saharan Africa 47 
focusing on causes other than malaria. 48 
Sources: A narrative literature review by searching the MEDLINE database, 49 
and recent conference abstracts. 50 
Content: Studies of multiple potential causes of fever are scarce, and for 51 
many participants the infecting organism remains unidentified, or multiple co-52 
infecting microorganisms are identified, and establishing causation is 53 
challenging. Among ambulatory patients, self-limiting arboviral infections and 54 
viral upper respiratory infections are common, occurring in up to 60% of 55 
children attending health centres. Among hospitalised patients there is a high 56 
prevalence of potentially fatal infections requiring specific treatment. Bacterial 57 
bloodstream infection, and bacterial zoonoses are major causes of fever. In 58 
recent years, the prevalence of antimicrobial resistance among bacterial 59 
isolates has increased, notably with spread of extended spectrum 60 
betalactamase-producing Enterobacteriaceae and fluoroquinolone resistant 61 
Salmonella enterica. Among those with HIV infection, Mycobacterium 62 
tuberculosis bacteraemia has been confirmed in up to 34.8% of patients with 63 
sepsis, and fungal infections such as cryptococcosis and histoplasmosis 64 
remain important. 65 
Implications: Understanding the local epidemiology of fever aetiology, and use 66 
of diagnostics including malaria and HIV rapid-diagnostic tests, guides 67 
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healthcare workers in the management of patients with fever. Current 68 
challenges for clinicians include assessing which ambulatory patients require 69 
antibacterial drugs, and identifying hospitalised patients infected with 70 
organisms that are not susceptible to empiric antibacterial regimens. 71 
 72 
ARTICLE 73 
Increasing recognition of causes of fever other than malaria 74 
The global burden of febrile illness, and the contribution of many fever-75 
inducing pathogens have been difficult to quantify and characterize. However, 76 
in sub-Saharan Africa it is clear that fever is a common symptom (1), and 77 
febrile illness a major cause of illness and death (2).  78 
 79 
Recently, there have been major advances in our knowledge of the causes of 80 
fever, which vary considerably across Africa. They are influenced by age and 81 
co-morbidities, and vary between ambulatory and hospitalised patients. 82 
Malaria remains a major cause of fever, although its incidence has been 83 
steadily declining since 2003 (3, 4). In places where the presence of fever 84 
used to be equated with malaria, malaria rapid diagnostic tests (RDTs) have 85 
identified the often large proportion of febrile patients who do not have 86 
malaria. Diagnosis of individual patients with febrile illness is challenging, due 87 
to the non-specific presentation of a broad variety of conditions, and the lack 88 
of available diagnostic tests. Therefore understanding the epidemiology of 89 
causes of fever has important implications for management of febrile patients. 90 
 91 
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We aim to review recent studies of community-acquired fever aetiology in 92 
sub-Saharan Africa focusing on causes other than malaria and describe the 93 
implications for diagnosis and management among ambulatory and 94 
hospitalised patients. 95 
Methodological notes 96 
Our review summarises the most relevant recent literature following a search 97 
of PubMed, and the personal perspectives of contributing experts. Our search 98 
strings are included as Appendix 1. Articles are included at the authors 99 
discretion.  100 
Studies investigating multiple causes of fever  101 
Studies investigating multiple causes of fever are scarce (5), particularly 102 
outside of East Africa. When performed, the proportion of patients without an 103 
aetiological diagnosis is often large, particularly among those with fatal febrile 104 
illness (6). This is partly due to the insensitivity of reference tests to diagnose 105 
common pathogens, but may also be due to as yet unrecognised pathogens.  106 
In addition, as few studies have enrolled healthy controls, determining 107 
whether an identified pathogen is the cause of fever is challenging, 108 
particularly when patients have evidence of infection with multiple 109 
microorganisms, or when tests used are not the reference standard and have 110 
sub-optimal specificity (7, 8).  Table 1 summarises selected studies 111 
investigating multiple causes of acute febrile illness. Table 1 demonstrates the 112 
variability in tests performed, the proportion of participants in whom no 113 
microorganism was detected, and the challenges of interpreting multiple 114 
positive diagnostic tests.  115 
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Table 1. Summary of selected studies investigating the aetiology of febrile illness in Africa, published 2013-2018 117 
 Study population Study size Testing Main diagnoses Comment and limitations 
D’Acremont, 
Tanzania, 2006 
(7) 
Paediatric  
Outpatient District Hospital 
HIV prevalence: not stated 
1005 Blood culture, respiratory virus and arboviral nucleic acid 
amplification testing (NAAT); arboviral serology; Leptospira,  
Coxiella, and Toxoplasma serology 
Viral aetiology in 78% of systemic infections, 100% of 
nasopharyngeal infections, and 51% of lower respiratory 
infections 
Overall: 9% malaria, 4.2% bacteraemia 
Challenging to determine causation due to high prevalence 
(76.9%) of co-infection and lack of healthy controls. 
Crump, 
Tanzania, 2007-
08  (6) 
Paediatric/ adult  
Referral hospitals 
Inpatient 
HIV prevalence    
<13 years 12.2% 
≥13 years : 39.0%  
870 Antigen detection for Cryptococcus, Histoplasma capsulatum, 
Legionella pneumophila, Streptococcus pneumoniae; blood 
culture (aerobic and mycobacterial); NAAT for arboviruses; 
serology for Brucella, Leptospira, Coxiella, and Rickettsia; thick 
and thin blood film for parasites 
<13 years: chikungunya 10.2%, leptospirosis 7.7%,  7.4% 
spotted fever group rickettsiosis (SFGR), 3.4% bacteraemia, 
2.6% Q fever, 2.0% brucellosis, 1.3% malaria, 0.9% fungaemia,   
≥13 years: 17.1% bacteraemia, 10.1% leptospirosis, 8.7%  
SFGR, 7.9% Q fever, 5.3% brucellosis, 5.7% chikungunya, 5.2% 
fungaemia, 3.5% mycobacteraemia,  2% malaria 
Large proportion of patients (64.0% aged <13 years, and 33.2%  
≥ 13 years without a aetiologic diagnosis. Respiratory viruses not 
sought. 
Baba , Nigeria, 
2006 (9) 
Adult 
Referral hospital 
Hospitalisation and HIV status 
not reported 
 
310 Serology for chikungunya, dengue, typhoid, West Nile virus 
(WNV), yellow fever; thick and thin film for malaria 
67% dengue, 50.2% chikungunya, 32.6% typhoid, 29.4% 
malaria, 24.9% WNV, 
The high prevalence of co-infection of mlalaria, serologically 
diagnosed typhoid, and arboviral infections highlights challenges 
of making diagnoses through non-reference standard tests 
Jacob , Uganda, 
2008-09 (10) 
Adult 
Referral hospital 
Inpatients with severe sepsis 
HIV prevalence 100% 
368 Antigen detection of Cryptococcus, blood culture (aerobic and 
mycobacterial); serology for HIV; thick and thin blood film for 
malaria,  
23.4% Mycobacterium tuberculosis, 11% bacteraemia, 4% non-
tuberculous mycobacteria, 2% Cryptococcus neoformans 
Highly selected population, with limmited breadth of pathogens 
investigated 
Chipwaza, 
Tanzania 2013 
(8, 11) 
District hospital 
Outpatient/ Inpatient 
HIV prevalence  not stated 
370 NAAT for influenza and dengue; serology for brucellosis, 
chikungunya, dengue, leptospirosis,  typhoid; thick and thin blood 
films for malaria; urine microscopy for bacteria 
<5 years: 31.3% dengue, 22.9% malaria, leptospirosis 19.5%, 
brucellosis 13.2%, typhoid 6.8%, 5.4% chikungunya, 1% 
influenza 
≥5 years: 81.1% dengue, 49.7% brucellosis, 31% leptospirosis, 
22.6% malaria, typhoid 14.4%, 4.1 influenza 
High prevalence of co-infection of serologically diagnosed 
typhoid and zoonotic infections highlights the challenges o 
determining causation when non-reference standard tests are 
used 
O’Meara , 
Maine Kenya, 
2011-12 (12, 
13) 
Paediatric 
District hospital 
Outpatient 
HIV prevalence 0.4% 
370  Antigen detection for group A Streptococcus, NAAT for 
adenovirus, influenza A and B, human metapneumovirus, 
parainfluenza virus 1-3, malaria, respiratory syncitial virus (RSV); 
serology for Rickettsia, Coxiella; thick and think films for 
parasites 
22.4% SFGR,  20.3% influenza A/B, 10.5% adenovirus, 10.1% 
parainfluenza virus 1-3, 8.9% Q fever, 5.3% RSV 5.2% malaria 
5.2%, 3.6% scrub typhus, hMNV 3.2%, group A Streptococcus 
2.3%,  1.0% typhus group Rickettsia 
Study notable for inclusion of healthy controls, in whom ≥1 
pathgen was detected in 49.1%. Limitations include a limited 
selection of pathogens sought.  
      
 118 
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Self-limited infections are a common cause of fever in 119 
ambulatory patients attending first level health facilities 120 
Recent studies have demonstrated the high prevalence of self-limited 121 
infections, particularly respiratory viruses. Among children with fever, 122 
attending lower-level health facilities in both Tanzania and Kenya the 123 
prevalence of viral respiratory pathogens was 41% (7, 12).  Arboviral 124 
infections, notably dengue, are also important causes of fever among both 125 
ambulatory and hospitalised patients (14). In one study conducted in multiple 126 
urban centres in Nigeria the prevalence of dengue virus infection was 23.4% 127 
(15).  There are also reports of multiple serotypes of dengue virus infection 128 
being highly prevalent, in both rural and urban areas of West Africa (15, 16), 129 
East Africa (17), and southern Africa (18, 19). Acute HIV infection also 130 
contributes to acute febrile illness and was identified in 1.7% and 3.3% of 131 
outpatients with fever in Kenya (20), and Mozambique respectively (21). 132 
 133 
Bacteraemia, particularly Salmonella enterica serovar Typhi, zoonotic 134 
bacterial infections, and HIV related opportunistic infections occur. However, 135 
these appear to be far less common among ambulatory patients than in those 136 
hospitalised with severe disease (7, 22, 23).  137 
 138 
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Multiple potential aetiologies of fever among hospitalised 139 
patients 140 
Bacterial bloodstream infection 141 
Bloodstream infection is a major cause of hospitalised fever in Africa. In 142 
patients with severe febrile illness, bacteraemia has been detected in 10.4% 143 
of patients in East Africa, and 12.4% of patients in West Africa (5). 144 
Immunosuppression due to HIV, and severe malnutrition remain significant 145 
risk factors for bacteraemia (24).  146 
 147 
The most prevalent bloodstream pathogens are nontyphoidal serovars of S. 148 
enterica and S. enterica serovar Typhi (22, 25-29), together accounting for 149 
46.2% of bacterial bloodstream isolates in Blantyre, Malawi during 1998-2016 150 
(30). The Typhoid Surveillance in Africa Program (TSAP) study has estimated 151 
the incidence of invasive nontyphoidal Salmonella (iNTS) disease to exceed 152 
100 cases per 100,000 population per year in many sites in Africa (29). Risk 153 
factors for iNTS include HIV infection, malnutrition, sickle cell disease, recent 154 
malaria infection, and severe anaemia (31-34). Declining malaria incidence 155 
and widespread availability of ART may contribute to the declining prevalence 156 
of iNTS in some areas (25, 35-39). 157 
 158 
Longitudinal data indicate re-emergence of S. enterica serovar Typhi. In 159 
Malawi it was identified in 1.0% of patients with bloodstream infection during 160 
1998-2009, and in 43.0% of positive blood cultures during 2014-16 (30). In 161 
TSAP, the incidence of S. enterica serovar Typhi bacteraemia was greater 162 
than 100 cases per 100,000 population per year at multiple rural and urban 163 
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sites in West Africa and East Africa.  Incidence was often highest among pre-164 
school children (29). 165 
 166 
Streptococcus pneumoniae remains another common cause of bacteraemia, 167 
particularly among children (22, 27-29, 40). Despite some replacement by 168 
non-vaccine strains among patients with invasive pneumococcal disease (41), 169 
recent data suggest a decline in invasive pneumococcal disease associated 170 
with use of pneumococcal conjugate vaccine and ART (25, 42, 43). Other 171 
commonly identified pathogens include Staphylococcus aureus (7, 29, 40), 172 
which at 54% of isolates was the most prevalent bloodstream pathogen 173 
among children from Guinea-Bissau (40), and Enterobacteriaceae (22, 25, 29, 174 
44). 175 
 176 
The prevalence of antimicrobial resistance (AMR) is a growing concern. 177 
Among Salmonella isolates multidrug resistance (resistance to ampicillin, 178 
chloramphenicol, and trimethoprim-sulfamethoxazole) has become common. 179 
In Ghana during 2010-2014, 56% of iNTS isolates and 63% of S. enterica 180 
serovar Typhi isolates were multi-drug resistant, and similar proportions have 181 
been seen in Burkina Faso, Kenya, and Tanzania (29, 39). In addition, there 182 
is emerging resistance to fluoroquinolones in S. enterica (26, 29, 30, 45), 183 
limiting oral outpatient treatment options. Reports also indicate increasing 184 
prevalence of resistance to extended-spectrum cephalosporins across Africa 185 
(29, 30), present in up to 56.5% nontyphoidal Salmonella bloodstream 186 
isolates in western Kenya (46). Resistance to extended spectrum 187 
cephalosporins among Salmonella enterica serovar Typhi remains rare, but 188 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
was recently identified in the Democratic Republic of Congo (47). AMR is also 189 
increasing among other invasive bacteria (48, 49). Of concern, there has been 190 
rapid expansion of fluoroquinolone and extended-spectrum beta-lactam 191 
resistant Enterobacteriaceae in Malawi (30), and it is likely that there are 192 
similar trends across Africa.  193 
Mycobacterial blood stream infections 194 
Mycobacterium tuberculosis is a major cause of bloodstream infection among 195 
adults living with HIV, but less so in children. M. tuberculosis was the cause of 196 
bacteraemia among 0.4% of children and 13.5% of adults with HIV in a recent 197 
systematic review (50). M. tuberculosis persists as a major cause of 198 
bloodstream infection in Zambia and Uganda despite the availability of ART 199 
(10, 51). 200 
 201 
Bacterial zoonoses 202 
Bacterial zoonoses are under-recognised causes of febrile illness in Africa. 203 
Major bacterial zoonoses include brucellosis, leptospirosis, Q fever, and 204 
rickettsiosis. The close association between people, livestock, and wildlife in 205 
both rural and urban areas of many African countries is a key driver of the 206 
high prevalence of zoonotic infection. 207 
 208 
Brucellosis 209 
Recent studies have found a prevalence of brucellosis among febrile patients 210 
in East Africa of between 2.6% and 22.4% (8, 52, 53). In a pastoralist area of 211 
rural Tanzania, Brucella melitensis was the most common bloodstream isolate 212 
(54).  Available data on risk factors for brucellosis in Africa suggest that 213 
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birthing livestock and drinking raw milk are important in sub-Saharan Africa, 214 
as they are elsewhere (55-57).  215 
 216 
Leptospirosis 217 
Testing for leptospirosis is reported infrequently among febrile patients, but 218 
when sought has been diagnosed in up to 8.4% of patients hospitalised with 219 
fever (58). Countries in tropical Africa may have among the highest 220 
incidences of leptospirosis globally (59), albeit with marked variation in 221 
incidence over time (60). Leptospirosis appears to be common in both rural 222 
and urban environments. In addition to rodents, livestock may play an 223 
important role as a source for human disease in Africa (61). 224 
 225 
Q fever 226 
A recent systematic review identified C. burnetii, the cause of Q fever, among 227 
6-9% of African patients with community acquired pneumonia, and 3-8% with 228 
undifferentiated febrile illness (62). In addition there have been reports of high 229 
prevalence of human seropositivity in Togo (63), and the Gambia (64). Cattle, 230 
goats, sheep, and camels have all been identified as having high prevalence 231 
of seroreactivity to C. burnetii and are likely to be important reservoirs of 232 
infection (62, 63).  233 
 234 
Rickettsial infections 235 
Rickettsioses are a frequent cause of fever in travellers returning from Africa 236 
(65). The major spotted fever group rickettsiosis (SFGR) in Africa is African 237 
tick-bite fever caused by Rickettsia africae. However, R. conorii, the cause of 238 
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Mediterranean spotted fever, has been identified in at least nine countries in 239 
sub-Saharan Africa (66). It is accepted that rickettsioses are common in 240 
Southern Africa (67), and they may be common across the continent. A recent 241 
study from Kenya identified SFGR in 22.4% of children with fever (13), and 242 
studies from Ethiopia and Tanzania also found a high prevalence (68, 69). In 243 
West Africa, the prevalence of SFGR is less well documented, but is likely to 244 
be high, as both tick vectors and human seropositivity are common (66). In 245 
addition, Rickettsia felis appears prevalent in West and Central Africa. 246 
Although R. felis has been identified among healthy individuals, data suggest 247 
it may be a common cause of fever (70).  248 
 249 
Relapsing fever 250 
Borrelia spp., the cause of relapsing fever, have been identified across Africa, 251 
are rarely sought in fever aetiology studies and may be under-recognised by 252 
clinicians (71). In Senegal B. crocidurae, which causes tick-borne relapsing 253 
fever, was detected in 7.3% of unselected adult and paediatric patients with 254 
fever. In Ethiopia B. recurrentis the cause of louse-borne relapsing fever was 255 
identified using blood film in 6.1% of healthy yekolotemaries (religious 256 
students) and 4.9% of healthy street children. The high prevalence among 257 
community members highlights the challenges of determining the prevalence 258 
of relapsing fever among patients with acute febrile illness. 259 
 260 
Protozoal infections 261 
Visceral leishmaniasis, which can cause fever, causes substantial morbidity in 262 
some areas of East Africa, particularly among people infected with HIV (72). 263 
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Human African trypanosomiasis (HAT) is endemic in parts of Central and 264 
West Africa, although control efforts aim to eliminate HAT as a public health 265 
problem are reducing incidence (73). The prevalence of these diseases in 266 
unselected patients with febrile illness is undetermined, but is likely to vary 267 
considerably by location. 268 
  269 
Fungal Infections 270 
Fungal infections remain an under-recognised cause of febrile illness among 271 
both HIV infected and uninfected hospitalised patients. Cryptococcal infection, 272 
which can result in disseminated disease and meningitis, remains a leading 273 
cause of death in HIV infected adults in Africa, despite increasingly 274 
widespread availability of ART. The epidemiology of cryptococcal disease is 275 
changing, while it is still most commonly identified at first presentation with 276 
HIV, presentation with cryptococcal disease is increasingly associated with 277 
treatment failure, default from treatment, and immune reconstitution early in 278 
the course of ART (74). Although there are few data, it is likely that 279 
histoplasmosis is endemic across large areas of Africa (75), and is often 280 
misdiagnosed as tuberculosis (76). 281 
 282 
Implications for diagnosis and treatment 283 
Management of patients presenting with fever requires appropriate supportive 284 
care, and correct antimicrobial therapy. Empiric management should be 285 
informed by knowledge of the local epidemiology of fever and AMR, HIV 286 
status of the patient, and results of malaria and HIV RDTs.  In countries with a 287 
high prevalence of malaria parasitaemia, consideration of non-malaria 288 
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aetiology is needed even in the presence of a positive malaria RDT, due to 289 
asymptomatic parasitaemia. Due to marked differences in disease severity 290 
and aetiology, management challenges for ambulant patients in the outpatient 291 
setting are different from those of patients hospitalised with severe febrile 292 
illness.  293 
Management of patients in first level health facilities 294 
The World Health Organisation (WHO) has proposed guidelines on the 295 
Integrated Management of Childhood Illness (IMCI) and the Integrated 296 
Management of Adolescent and Adult Illness (IMAI). Such guidance informs 297 
management decisions regarding appropriate supportive care, who should be 298 
referred to a higher level health facility, and who needs anti-microbial drugs 299 
(77, 78). Updates reflecting the epidemiologic and management advances are 300 
needed to ensure the guidelines remain safe and effective. In malaria-301 
endemic areas, the introduction of malaria RDTs has led to more rational use 302 
of antimalarial drugs (79), but surprisingly over-prescription of antibacterial 303 
drugs (80, 81). Due to the high prevalence of self-limiting viral infections at 304 
first level health facilities, the challenge in management of ambulatory patients 305 
is to identify those from whom antibacterial drugs can be safely withheld. 306 
Research efforts to reduce over-prescription include investigating refinement 307 
of clinical severity criteria, and the use of biomarkers to detect severe 308 
bacterial disease. Studies addressing biomarkers are described in a separate 309 
review within this issue. 310 
Identification of the most severely unwell 311 
Among hospitalised patients, there are a large number of potentially fatal 312 
causes of fever that cannot be reliably separated on clinical grounds. 313 
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Management is guided by illness severity, and WHO pocketbooks help 314 
clinicians identify severe disease (82, 83). Recent attempts to improve 315 
identification of those with severe illness with prediction scores, such as the 316 
quick sequential organ failure assessment (84) and the universal vital 317 
assessment score (85), have shown ability to identify those at greatest risk of 318 
death. These scores could help clinicians better target those needing broad-319 
spectrum antimicrobial therapy and more intensive supportive care.  320 
Identification of those with bacterial infections that are not susceptible 321 
to first-line antimicrobials 322 
IMCI and IMAI handbooks recommend an extended-spectrum cephalosporin, 323 
or ampicillin plus gentamicin, as suitable broad-spectrum antimicrobial 324 
therapy for those with severe febrile illness. The diversity of pathogens and 325 
bacterial AMR in different settings raises the possibility that this generic 326 
guidance is insufficient. The WHO pocketbooks do not address severe 327 
disease due to bacterial pathogens that are not susceptible to these agents, 328 
nor in which patients with undifferentiated fever to use anti-fungal and anti-329 
tuberculosis drugs (82, 83). Local microbiologic data in aggregate are 330 
invaluable for tailoring of empiric management guidelines. Depending on local 331 
epidemiology, consideration should be given to additional therapies including 332 
carbapenem and tetracycline group antibacterials, antifungal agents, and anti-333 
tuberculosis medications. There is no clinical trial evidence currently to 334 
support empiric treatment with tetracycline in patients in Africa with severe or 335 
prolonged fever. However, the high prevalence of relapsing fever, 336 
rickettsiosis, and Q fever suggest a role. In areas with a high prevalence of 337 
ESBL-producing organisms, such western Kenya where ESBL-producing 338 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 17 
nontyphoidal S. enterica is the leading cause of bacteraemia (46), empiric 339 
regimens active against ESBL-producing organisms must be considered for 340 
patients with sepsis. Such escalation in antimicrobial therapy must be in 341 
concert with robust anti-microbial stewardship programmes. 342 
Use of rapid diagnostic tests to guide empiric treatment of M. 343 
tuberculosis and Cryptococcus spp. 344 
Provider-initiated HIV testing is recommended for all patients in countries with 345 
a high prevalence of HIV (78, 83). HIV testing is invaluable for managing 346 
febrile patients in such countries, as the results inform the probability that the 347 
patient might have cryptococcal disease or disseminated tuberculosis (78, 348 
83). Among those with HIV, the cryptococcal antigen RDTs are useful to 349 
diagnose cryptococcal disease (86). Early anti-tuberculosis therapy may 350 
improve outcomes in the most severely unwell patients infected with 351 
tuberculosis (87, 88). Although trials are needed, there is a case for further 352 
development of RDTs to diagnose disseminated tuberculosis (89), or the 353 
inclusion of anti-tuberculosis therapy as empiric treatment for adults with  354 
advanced HIV who present with sepsis (90).  355 
Ongoing patient management: establishing a microbiological diagnosis 356 
to inform therapeutic strategy  357 
Microbiological diagnosis informs ongoing patient management, especially 358 
when the infection is not responsive to empiric agents, requires multi-drug 359 
therapy, or prolonged treatment. The laboratory capacity to identify patients 360 
infected with the broad range of organisms that can cause fever is not 361 
available in most hospitals in sub-Saharan Africa (91). There is therefore need 362 
for either laboratory development, which may be a cost-effective approach 363 
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(92), or continued development of sentinel sites to monitor both aetiology of 364 
fever and AMR.  365 
 366 
Conclusions 367 
The causes of non-malarial fever are diverse and yet to be fully determined. In 368 
addition to bacterial bloodstream infection, recent studies highlight the role of 369 
viral pathogens, bacterial zoonoses, disseminated tuberculosis, and 370 
cryptoccal disease, for which the antimicrobials currently recommended by 371 
the World Health Organisation for acute febrile illness may not be effective. In 372 
addition, there is evidence of increasing AMR, particularly among Salmonella 373 
and other gram negative bacteria. These developments highlight the critical 374 
role of sentinel surveillance sites that can inform in real-time the epidemiology 375 
of febrile illness. There is a need to incorporate the evolving complexity in 376 
causes of acute febrile illness into evidenced based algorthims to manage 377 
patients for whom reliable and relevant diagnostic services are not available.  378 
 379 
Conflict of Interest  380 
All authors declare they have no conflict of interest. 381 
Funding declaration  382 
MJM received support from University of Otago scholarships: the Frances G. 383 
Cotter Scholarship and the MacGibbon Travel Fellowship. JAC was supported 384 
by the joint US National Institutes of Health (NIH:www.nih.gov)-National 385 
Science Foundation (NSF:www.nsf.gov) Ecology of Infectious Disease 386 
program (R01TW009237), the US National Institutes of Health Institute of 387 
Allergy and Infectious Disease (R01 AI121378), and the Research Councils 388 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 19 
UK, Department for International Development (UK) and UK Biotechnology 389 
and Biological Sciences Research Council (BBSRC:www.bbsrc.ac.uk) (grant 390 
numbers BB/J010367/1, BB/L018926, BB/L017679, BB/L018845). 391 
 392 
REFERENCES 393 
 394 
1. Prasad N, Sharples KJ, Murdoch DR, Crump JA. Community 395 
prevalence of fever and relationship with malaria among infants and children 396 
in low-resource areas. Am J Trop Med Hyg. 2015;93(1):178-80. 397 
2. Global Burden of Disease Study 2015. Global Burden of Disease Study 398 
2015 (GBD 2015) Results Seattle, United States of America: Insititute for 399 
Health Metrics and Evaluation (IHME); 2016 [7 March 2017]. Available from: 400 
http://ghdx.healthdata.org/gbd-results-tool  401 
3. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, 402 
et al. Global, regional, and national incidence and mortality for HIV, 403 
tuberculosis, and malaria during 1990–2013: a systematic analysis for the 404 
Global Burden of Disease Study 2013. The Lancet. 2014;384(9947):1005-70. 405 
4. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et 406 
al. The effect of malaria control on Plasmodium falciparum in Africa between 407 
2000 and 2015. Nature. 2015;526(7572):207-11. 408 
5. Prasad N, Murdoch DR, Reyburn H, Crump JA. Etiology of Severe 409 
Febrile Illness in Low- and Middle-Income Countries: A Systematic Review. 410 
PLoS One. 2015;10(6):e0127962. 411 
6. Crump JA, Morrissey AB, Nicholson WL, Massung RF, Stoddard RA, 412 
Galloway RL, et al. Etiology of severe non-malaria febrile illness in Northern 413 
Tanzania: a prospective cohort study. PLoS Negl Trop Dis. 2013;7(7):e2324. 414 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20 
7. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-415 
Maro J, et al. Beyond malaria - causes of fever in outpatient Tanzanian 416 
children. N Engl J Med. 2014;370(9):809-17. 417 
8. Chipwaza B, Mhamphi GG, Ngatunga SD, Selemani M, Amuri M, 418 
Mugasa JP, et al. Prevalence of bacterial febrile illnesses in children in Kilosa 419 
district, Tanzania. PLoS Negl Trop Dis. 2015;9(5):e0003750. 420 
9. Baba M, Logue CH, Oderinde B, Abdulmaleek H, Williams J, Lewis J, 421 
et al. Evidence of arbovirus co-infection in suspected febrile malaria and 422 
typhoid patients in Nigeria. J Infect Dev Ctries. 2013;7(1):51-9. 423 
10. Jacob ST, Pavlinac PB, Nakiyingi L, Banura P, Baeten JM, Morgan K, 424 
et al. Mycobacterium tuberculosis bacteremia in a cohort of HIV-infected 425 
patients hospitalized with severe sepsis in Uganda-high frequency, low clinical 426 
suspicion [corrected] and derivation of a clinical prediction score. PLoS One. 427 
2013;8(8):e70305. 428 
11. Chipwaza B, Mugasa JP, Selemani M, Amuri M, Mosha F, Ngatunga 429 
SD, et al. Dengue and Chikungunya fever among viral diseases in outpatient 430 
febrile children in Kilosa district hospital, Tanzania. PLoS Negl Trop Dis. 431 
2014;8(11):e3335. 432 
12. O'Meara WP, Mott JA, Laktabai J, Wamburu K, Fields B, Armstrong J, 433 
et al. Etiology of pediatric fever in western Kenya: a case-control study of 434 
falciparum malaria, respiratory viruses, and streptococcal pharyngitis. Am J 435 
Trop Med Hyg. 2015;92(5):1030-7. 436 
13. Maina AN, Farris CM, Odhiambo A, Jiang J, Laktabai J, Armstrong J, 437 
et al. Q fever, scrub typhus, and rickettsial diseases in children, Kenya, 2011–438 
2012. Emerging infectious diseases. 2016;22(5):883. 439 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 21 
14. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus 440 
infection in Africa. Emerg Infect Dis. 2011;17(8):1349-54. 441 
15. Onoja AB, Adeniji JA, Olaleye OD. High rate of unrecognized dengue 442 
virus infection in parts of the rainforest region of Nigeria. Acta Trop. 443 
2016;160:39-43. 444 
16. Ridde V, Agier I, Bonnet E, Carabali M, Dabire KR, Fournet F, et al. 445 
Presence of three dengue serotypes in Ouagadougou (Burkina Faso): 446 
research and public health implications. Infect Dis Poverty. 2016;5:23. 447 
17. Ngoi CN, Price MA, Fields B, Bonventure J, Ochieng C, Mwashigadi G, 448 
et al. Dengue and chikungunya virus infections among young febrile adults 449 
evaluated for acute HIV-1 infection in coastal Kenya. PLoS One. 450 
2016;11(12):e0167508. 451 
18. Parreira R, Conceicao C, Centeno-Lima S, Marques N, Saraiva da 452 
Cunha J, Abreu C, et al. Angola's 2013 dengue outbreak: clinical, laboratory 453 
and molecular analyses of cases from four Portuguese institutions. J Infect 454 
Dev Ctries. 2014;8(9):1210-5. 455 
19. Massangaie M, Pinto G, Padama F, Chambe G, da Silva M, Mate I, et 456 
al. Clinical and epidemiological characterization of the first recognized 457 
outbreak of dengue virus-type 2 in Mozambique, 2014. Am J Trop Med Hyg. 458 
2016;94(2):413-6. 459 
20. Sanders EJ, Mugo P, Prins HA, Wahome E, Thiong'o AN, Mwashigadi 460 
G, et al. Acute HIV-1 infection is as common as malaria in young febrile adults 461 
seeking care in coastal Kenya. AIDS. 2014;28(9):1357-63. 462 
21. Serna-Bolea C, Munoz J, Almeida JM, Nhacolo A, Letang E, 463 
Nhampossa T, et al. High prevalence of symptomatic acute HIV infection in an 464 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 22 
outpatient ward in southern Mozambique: identification and follow-up. AIDS. 465 
2010;24(4):603-8. 466 
22. Hildenwall H, Amos B, Mtove G, Muro F, Cederlund K, Reyburn H. 467 
Causes of non-malarial febrile illness in outpatients in Tanzania. Trop Med Int 468 
Health. 2016;21(1):149-56. 469 
23. Mahende C, Ngasala B, Lusingu J, Butichi A, Lushino P, Lemnge M, et 470 
al. Bloodstream bacterial infection among outpatient children with acute febrile 471 
illness in north-eastern Tanzania. BMC Res Notes. 2015;8:289. 472 
24. Huson MA, Stolp SM, van der Poll T, Grobusch MP. Community-473 
acquired bacterial bloodstream infections in HIV-infected patients: a 474 
systematic review. Clin Infect Dis. 2014;58(1):79-92. 475 
25. Feasey NA, Houston A, Mukaka M, Komrower D, Mwalukomo T, 476 
Tenthani L, et al. A reduction in adult blood stream infection and case fatality 477 
at a large African hospital following antiretroviral therapy roll-out. PLoS One. 478 
2014;9(3):e92226. 479 
26. Feasey NA, Masesa C, Jassi C, Faragher EB, Mallewa J, Mallewa M, 480 
et al. Three epidemics of invasive multidrug-resistant Salmonella bloodstream 481 
infection in Blantyre, Malawi, 1998-2014. Clin Infect Dis. 2015;61 Suppl 482 
4:S363-71. 483 
27. Crump JA, Ramadhani HO, Morrissey AB, Msuya LJ, Yang LY, Chow 484 
SC, et al. Invasive bacterial and fungal infections among hospitalized HIV-485 
infected and HIV-uninfected children and infants in northern Tanzania. Trop 486 
Med Int Health. 2011;16(7):830-7. 487 
28. Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, 488 
Yang LY, et al. Invasive bacterial and fungal infections among hospitalized 489 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 23 
HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. 490 
Clin Infect Dis. 2011;52(3):341-8. 491 
29. Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb MA, Ali 492 
M, et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a 493 
multicentre population-based surveillance study. Lancet Glob Health. 494 
2017;5(3):e310-e23. 495 
30. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, et 496 
al. Trends in antimicrobial resistance in bloodstream infection isolates at a 497 
large urban hospital in Malawi (1998-2016): a surveillance study. Lancet Infect 498 
Dis. 2017;17(10):1042-52. 499 
31. Uche IV, MacLennan CA, Saul A. A systematic review of the incidence, 500 
risk factors and case fatality rates of invasive nontyphoidal Salmonella (iNTS) 501 
Disease in Africa (1966 to 2014). PLoS Negl Trop Dis. 2017;11(1):e0005118. 502 
32. Park SE, Pak GD, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, et al. The 503 
relationship between invasive nontyphoidal Salmonella disease, other 504 
bacterial bloodstream infections, and malaria in sub-Saharan Africa. Clin 505 
Infect Dis. 2016;62 Suppl 1:S23-31. 506 
33. Takem EN, Roca A, Cunnington A. The association between malaria 507 
and non-typhoid Salmonella bacteraemia in children in sub-Saharan Africa: a 508 
literature review. Malar J. 2014;13:400. 509 
34. Biggs HM, Lester R, Nadjm B, Mtove G, Todd JE, Kinabo GD, et al. 510 
Invasive Salmonella infections in areas of high and low malaria transmission 511 
intensity in Tanzania. Clin Infect Dis. 2014;58(5):638-47. 512 
35. Scott JA, Berkley JA, Mwangi I, Ochola L, Uyoga S, Macharia A, et al. 513 
Relation between falciparum malaria and bacteraemia in Kenyan children: a 514 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24 
population-based, case-control study and a longitudinal study. Lancet. 515 
2011;378(9799):1316-23. 516 
36. Mackenzie G, Ceesay SJ, Hill PC, Walther M, Bojang KA, Satoguina J, 517 
et al. A decline in the incidence of invasive non-typhoidal Salmonella infection 518 
in The Gambia temporally associated with a decline in malaria infection. PLoS 519 
One. 2010;5(5):e10568. 520 
37. Feasey NA, Everett D, Faragher EB, Roca-Feltrer A, Kang'ombe A, 521 
Denis B, et al. Modelling the contributions of malaria, HIV, malnutrition and 522 
rainfall to the decline in paediatric invasive non-typhoidal Salmonella disease 523 
in Malawi. PLoS Negl Trop Dis. 2015;9(7):e0003979. 524 
38. Keddy KH, Takuva S, Musekiwa A, Puren AJ, Sooka A, Karstaedt A, et 525 
al. An association between decreasing incidence of invasive non-typhoidal 526 
salmonellosis and increased use of antiretroviral therapy, Gauteng Province, 527 
South Africa, 2003-2013. PLoS One. 2017;12(3):e0173091. 528 
39. Muthumbi E, Morpeth SC, Ooko M, Mwanzu A, Mwarumba S, Mturi N, 529 
et al. Invasive salmonellosis in Kilifi, Kenya. Clin Infect Dis. 2015;61 Suppl 530 
4:S290-301. 531 
40. Isendahl J, Manjuba C, Rodrigues A, Xu W, Henriques-Normark B, 532 
Giske CG, et al. Prevalence of community-acquired bacteraemia in Guinea-533 
Bissau: an observational study. BMC Infect Dis. 2014;14:3859. 534 
41. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of 535 
Streptococcus pneumoniae causing invasive disease in children in the post-536 
PCV era: A systematic review and meta-analysis. PLoS One. 537 
2017;12(5):e0177113. 538 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25 
42. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von 539 
Mollendorf C, et al. Effects of vaccination on invasive pneumococcal disease 540 
in South Africa. N Engl J Med. 2014;371(20):1889-99. 541 
43. Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et 542 
al. Effect of the introduction of pneumococcal conjugate vaccination on 543 
invasive pneumococcal disease in The Gambia: a population-based 544 
surveillance study. Lancet Infect Dis. 2016;16(6):703-11. 545 
44. Akoua-Koffi C, Tia H, Plo JK, Monemo P, Cisse A, Yao C, et al. 546 
Epidemiology of community-onset bloodstream infections in Bouake, central 547 
Cote d'Ivoire. New Microbes New Infect. 2015;7:100-4. 548 
45. Feasey NA, Cain AK, Msefula CL, Pickard D, Alaerts M, Aslett M, et al. 549 
Drug resistance in Salmonella enterica ser. Typhimurium bloodstream 550 
infection, Malawi. Emerg Infect Dis. 2014;20(11):1957-9. 551 
46. Oneko M, Kariuki S, Muturi-Kioi V, Otieno K, Otieno VO, Williamson 552 
JM, et al. Emergence of community-acquired, multidrug-resistant invasive 553 
nontyphoidal Salmonella disease in rural western Kenya, 2009–2013. Clinical 554 
Infectious Diseases. 2015;61(suppl_4):S310-S6. 555 
47. Phoba M-F, Barbé B, Lunguya O, Masendu L, Lulengwa D, Dougan G, 556 
et al. Salmonella enterica serovar Typhi producing CTX-M-15 extended 557 
spectrum β-lactamase in the Democratic Republic of the Congo. Clinical 558 
Infectious Diseases. 2017:cix342. 559 
48. Leopold SJ, van Leth F, Tarekegn H, Schultsz C. Antimicrobial drug 560 
resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a 561 
systematic review. J Antimicrob Chemother. 2014;69(9):2337-53. 562 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 26 
49. Pons MJ, Vubil D, Guiral E, Jaintilal D, Fraile O, Soto SM, et al. 563 
Characterisation of extended-spectrum β-lactamases among Klebsiella 564 
pneumoniae isolates causing bacteraemia and urinary tract infection in 565 
Mozambique. Journal of Global Antimicrobial Resistance. 2015;3(1):19-25. 566 
50. Pavlinac P, Lokken E, Walson J, Richardson B, Crump J, John-Stewart 567 
G. Mycobacterium tuberculosis bacteremia in adults and children: a 568 
systematic review and meta-analysis. The International Journal of 569 
Tuberculosis and Lung Disease. 2016;20(7):895-902. 570 
51. Muchemwa L, Shabir L, Andrews B, Bwalya M. High prevalence of 571 
Mycobacterium tuberculosis bacteraemia among a cohort of HIV-infected 572 
patients with severe sepsis in Lusaka, Zambia. Int J STD AIDS. 2016. 573 
52. Animut A, Mekonnen Y, Shimelis D, Ephraim E. Febrile illnesses of 574 
different etiology among outpatients in four health centers in northwestern 575 
Ethiopia. Jpn J Infect Dis. 2009;62(2):107-10. 576 
53. Bouley AJ, Biggs HM, Stoddard RA, Morrissey AB, Bartlett JA, 577 
Afwamba IA, et al. Brucellosis among hospitalized febrile patients in northern 578 
Tanzania. Am J Trop Med Hyg. 2012;87(6):1105-11. 579 
54. Bodenham  RF, Lukambagire A-H, Buza JJ, Kazwala RR, Maro VP, 580 
Mmbaga BT, et al. Brucella among febrile outpatients and their household 581 
members in northern Tanzania.  Royal Society of Tropical Medicine and 582 
Hygeine East African research in progress meeting; 28 Sep - 1 Oct 2017; 583 
Moshi, Tanzania. 584 
55. John K, Fitzpatrick J, French N, Kazwala R, Kambarage D, Mfinanga 585 
GS, et al. Quantifying risk factors for human brucellosis in rural northern 586 
Tanzania. PLoS One. 2010;5(4):e9968. 587 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 27 
56. Ducrotoy M, Bertu WJ, Matope G, Cadmus S, Conde-Alvarez R, Gusi 588 
AM, et al. Brucellosis in sub-Saharan Africa: current challenges for 589 
management, diagnosis and control. Acta Trop. 2017;165:179-93. 590 
57. Cash-Goldwasser S, Maze MJ, Rubach MP, Biggs HM, Stoddard RA, 591 
Sharples KJ, et al. Risk factors for human brucellosis in northern Tanzania. 592 
Am J Trop Med Hyg. 2017. 593 
58. Allan KJ, Biggs HM, Halliday JE, Kazwala RR, Maro VP, Cleaveland S, 594 
et al. Epidemiology of leptospirosis in Africa: a systematic review of a 595 
neglected zoonosis and a paradigm for 'One Health' in Africa. PLoS Negl Trop 596 
Dis. 2015;9(9):e0003899. 597 
59. Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-598 
Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic 599 
review. PLoS Negl Trop Dis. 2015;9(9):e0003898. 600 
60. Maze MJ, Biggs HM, Rubach MP, Galloway RL, Cash-Goldwasser S, 601 
Allan KJ, et al. Comparison of the estimated incidence of acute leptospirosis 602 
in the Kilimanjaro Region of Tanzania between 2007-08 and 2012-14. PLoS 603 
Negl Trop Dis. 2016;10(12):e0005165. 604 
61. Maze MJ, Cash-Goldwasser S, Rubach MP, Biggs HM, Galloway RL, 605 
Sharples KJ, et al., editors. Risk factors for acute human leptospirosis in 606 
northern Tanzania. In: Program and abstracts of the American Society of 607 
Tropical Medicine and Hygiene 65th Annual Meeting; 2016 November 13-17, 608 
2016; Atlanta, Georgia, USA. 609 
62. Vanderburg S, Rubach MP, Halliday JE, Cleaveland S, Reddy EA, 610 
Crump JA. Epidemiology of Coxiella burnetii infection in Africa: a OneHealth 611 
systematic review. PLoS Negl Trop Dis. 2014;8(4):e2787. 612 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 28 
63. Dean AS, Bonfoh B, Kulo AE, Boukaya GA, Amidou M, Hattendorf J, et 613 
al. Epidemiology of brucellosis and Q Fever in linked human and animal 614 
populations in northern Togo. PLoS One. 2013;8(8):e71501. 615 
64. Bok J, Hogerwerf L, Germeraad EA, Roest HI, Faye‐Joof T, Jeng M, 616 
et al. Coxiella burnetii (Q fever) prevalence in associated populations of 617 
humans and small ruminants in The Gambia. Tropical Medicine & 618 
International Health. 2017;22(3):323-31. 619 
65. Jensenius M, Davis X, von Sonnenburg F, Schwartz E, Keystone JS, 620 
Leder K, et al. Multicenter GeoSentinel analysis of rickettsial diseases in 621 
international travelers, 1996-2008. Emerg Infect Dis. 2009;15(11):1791-8. 622 
66. Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, 623 
Kernif T, et al. Update on tick-borne rickettsioses around the world: a 624 
geographic approach. Clin Microbiol Rev. 2013;26(4):657-702. 625 
67. Raoult D, Fournier PE, Fenollar F, Jensenius M, Prioe T, de Pina JJ, et 626 
al. Rickettsia africae, a tick-borne pathogen in travelers to sub-Saharan Africa. 627 
N Engl J Med. 2001;344(20):1504-10. 628 
68. Prabhu M, Nicholson WL, Roche AJ, Kersh GJ, Fitzpatrick KA, Oliver 629 
LD, et al. Q fever, spotted fever group, and typhus group rickettsioses among 630 
hospitalized febrile patients in northern Tanzania. Clin Infect Dis. 631 
2011;53(4):e8-15. 632 
69. Aarsland SJ, Castellanos-Gonzalez A, Lockamy KP, Mulu-Droppers R, 633 
Mulu M, White AC, et al. Treatable bacterial infections are underrecognized 634 
causes of fever in Ethiopian children. Am J Trop Med Hyg. 2012;87(1):128-33. 635 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 29 
70. Mourembou G, Lekana-Douki JB, Mediannikov O, Nzondo SM, Kouna 636 
LC, Essone JC, et al. Possible role of Rickettsia felis in acute febrile illness 637 
among children in Gabon. Emerg Infect Dis. 2015;21(10):1808-15. 638 
71. Elbir H, Raoult D, Drancourt M. Relapsing fever borreliae in Africa. Am 639 
J Trop Med Hyg. 2013;89(2):288-92. 640 
72. Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. 641 
Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop 642 
Dis. 2014;8(6):e2869. 643 
73. Simarro PP, Cecchi G, Franco JR, Paone M, Diarra A, Priotto G, et al. 644 
Monitoring the progress towards the elimination of gambiense human African 645 
trypanosomiasis. PLoS Negl Trop Dis. 2015;9(6):e0003785. 646 
74. Scriven JE, Lalloo DG, Meintjes G. Changing epidemiology of HIV-647 
associated cryptococcosis in sub-Saharan Africa. Lancet Infect Dis. 648 
2016;16(8):891-2. 649 
75. Valero C, Gago S, Monteiro MC, Alastruey-Izquierdo A, Buitrago MJ. 650 
African histoplasmosis: new clinical and microbiological insights. Med Mycol. 651 
2017. 652 
76. Lofgren SM, Kirsch EJ, Maro VP, Morrissey AB, Msuya LJ, Kinabo GD, 653 
et al. Histoplasmosis among hospitalized febrile patients in northern Tanzania. 654 
Trans R Soc Trop Med Hyg. 2012;106(8):504-7. 655 
77. Integrated Management of Adolescent and Adult Illness, acute illness: 656 
guidelines for first-level facility health workers at health centre and district 657 
outpatient clinic. Geneva: World Health Organization; 2009. 658 
78. Integrated Management of Childhood Illness Chart Booklet. Geneva: 659 
World Health Organization, 2014. 660 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 30 
79. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya S, Whitty CJ, et 661 
al. The impact of response to the results of diagnostic tests for malaria: cost-662 
benefit analysis. BMJ. 2008;336(7637):202-5. 663 
80. Hopkins H, Bruxvoort KJ, Cairns ME, Chandler CI, Leurent B, Ansah 664 
EK, et al. Impact of introduction of rapid diagnostic tests for malaria on 665 
antibiotic prescribing: analysis of observational and randomised studies in 666 
public and private healthcare settings. BMJ. 2017;356:j1054. 667 
81. Johansson EW, Selling KE, Nsona H, Mappin B, Gething PW, Petzold 668 
M, et al. Integrated paediatric fever management and antibiotic over-treatment 669 
in Malawi health facilities: data mining a national facility census. Malar J. 670 
2016;15(1):396. 671 
82. Organization WH. Pocket book of hospital care for children: guidelines 672 
for the management of common childhood illnesses: World Health 673 
Organization; 2013. 674 
83. IMAI district clinician manual: hospital care for adolescents and adults: 675 
guidelines for the management of illnesses with limited-resources. Geneva: 676 
World Health Organization, 2011. 677 
84. Huson MA, Kalkman R, Grobusch MP, van der Poll T. Predictive value 678 
of the qSOFA score in patients with suspected infection in a resource limited 679 
setting in Gabon. Travel Medicine and Infectious Disease. 2017;15:76-7. 680 
85. Moore CC, Hazard R, Saulters KJ, Ainsworth J, Adakun SA, Amir A, et 681 
al. Derivation and validation of a universal vital assessment (UVA) score: a 682 
tool for predicting mortality in adult hospitalised patients in sub-Saharan 683 
Africa. BMJ Global Health. 2017;2(2):e000344. 684 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 31 
86. Mamuye AT, Bornstein E, Temesgen O, Blumberg HM, Kempker RR. 685 
Point-of-care testing for cryptococcal disease among hospitalized Human 686 
Immunodeficiency Virus–infected adults in Ethiopia. Am J Trop Med Hyg. 687 
2016;95(4):786-92. 688 
87. Kethireddy S, Light RB, Mirzanejad Y, Maki D, Arabi Y, Lapinsky S, et 689 
al. Mycobacterium tuberculosis septic shock. Chest. 2013;144(2):474-82. 690 
88. Katagira W, Walter ND, Den Boon S, Kalema N, Ayakaka I, Vittinghoff 691 
E, et al. Empiric TB Treatment of Severely Ill Patients With HIV and Presumed 692 
Pulmonary TB Improves Survival. J Acquir Immune Defic Syndr. 693 
2016;72(3):297-303. 694 
89. Manabe YC, Nonyane BA, Nakiyingi L, Mbabazi O, Lubega G, Shah M, 695 
et al. Point-of-care lateral flow assays for tuberculosis and cryptococcal 696 
antigenuria predict death in HIV infected adults in Uganda. PloS One. 697 
2014;9(7):e101459. 698 
90. Cummings MJ, O'Donnell MR. Inverting the pyramid: increasing 699 
awareness of mycobacterial sepsis in sub-Saharan Africa. Int J Tuberc Lung 700 
Dis. 2015;19(10):1128-34. 701 
91. Schroeder LF, Amukele T. Medical laboratories in sub-Saharan Africa 702 
that meet international quality standards. Am J Clin Pathol. 2014;141(6):791-703 
5. 704 
92. Penno EC, Baird SJ, Crump JA. Cost-effectiveness of surveillance for 705 
bloodstream infections for sepsis management in low-resource settings. Am J 706 
Trop Med Hyg. 2015;93(4):850-60. 707 
 708 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Appendix 1. Search strategy for identifying papers for inclusion in this narrative review 
of the recent advances in the epidemiology of febrile illness in sub-Saharan Africa  
 
Search Date: 15 September 2017 
 
Search terms: 
[African country names] AND [Fever] 
[African country names] AND [Non-malarial fever.mp] AND [Epidemiology] 
[African country names] AND [Bacteremia]  
[African country names] AND [Disseminated tuberculosis.mp OR Tuberculosis, miliary] 
[African country names] AND [Brucellosis] 
[African country names] AND [Leptospirosis] 
[African country names] AND [Coxiella burnetii OR Q fever] 
[African country names] AND [Rickettsia infections] 
[African country names] AND [Histoplasmosis] 
[African country names] AND [Cryptococcosis] 
[African country names] AND [Viruses] 
[African country names] AND [Dengue] 
[African country names] AND [Respiratory Virus] 
[African country names] AND [Salmonella] 
[African country names] AND [Drug resistance, bacterial] 
 
[African country names]= Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR 
Cameroon OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo 
(Brazzaville) OR Congo (Democratic Republic) OR Côte d'Ivoire OR Djibouti OR Equatorial 
Guinea OR Eritrea OR Ethiopia OR Gabon OR The Gambia OR Ghana OR Guinea OR 
Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR 
Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR Réunion 
OR Rwanda OR Sao Tome and Principe OR Senegal OR Seychelles OR Sierra Leone OR 
Somalia OR South Africa OR Sudan OR Swaziland OR Tanzania OR Togo OR Uganda OR 
Western Sahara OR Zambia OR Zimbabwe OR Africa, Eastern OR South Africa OR Africa 
OR Africa, Western OR Africa, Southern OR Africa, Central OR "Africa South of the Sahara"  
 
Year limitation: 2012-2017 (inclusive) 
